ArticleAging2020
A three-lncRNA signature predicts clinical outcomes in low-grade glioma patients after radiotherapy.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Targeting non-coding RNAs to overcome resistance and improving outcomes in glioblastoma.Global medical genetics · 2025Review
- Predictive molecular biomarkers of radiosensitivity in adult glioma: a narrative review.BMC cancer · 2025Review
- DNA repair in tumor radioresistance: insights from fruit flies genetics.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.Scientific reports · 2024Article
- Exploration of the radiosensitivity-related prognostic risk signature in patients with glioma: evidence from microarray data.Journal of translational medicine · 2023Article
- Decreased SPTBN2 expression regulated by the ceRNA network is associated with poor prognosis and immune infiltration in low‑grade glioma.Experimental and therapeutic medicine · 2023Article
- Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis.Annals of medicine · 2023Review
- Radio-lncRNAs: Biological Function and Potential Use as Biomarkers for Personalized Oncology.Journal of personalized medicine · 2022Review
- Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.Scientific reports · 2022Article
- The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review.Frontiers in pharmacology · 2022Review
- The Roles Played by Long Non-Coding RNAs in Glioma Resistance.International journal of molecular sciences · 2021Review
- Article
- Diagnosis and Management of Glioblastoma: A Comprehensive Perspective.Journal of personalized medicine · 2021Review
- An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma.Cancer medicine · 2021Article
- Bioinformatic Analyses of the Ferroptosis-Related lncRNAs Signature for Ovarian Cancer.Frontiers in molecular biosciences · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although radiation therapy (RT) plays a critical role in the treatment of low-grade glioma (LGG), many patients suffer from adverse effects without experiencing survival benefits. In various carcinomas, long non-coding RNAs (lncRNAs) contribute to pathogenic processes, including tumorigenesis, metastasis, chemoresistance, and radioresistance. Currently, the role of lncRNAs in the radiosensitivity of LGG is largely unknown. Here, we downloaded clinical data for 167 LGG patients from The Cancer Genome Atlas database and divided them between radiosensitive and radioresistant groups based on their clinical outcomes after receiving radiotherapy. We identified 37 lncRNAs that were differentially expressed (DElncRNAs) between the groups. Functional enrichment analysis revealed that their potential target mRNAs were mainly enriched in the PI3K-Akt and MAPK signaling pathways and in DNA damage response. Kaplan-Meier survival analysis revealed that increased expression of six lncRNAs was significantly associated with radiosensitivity. We then developed a risk signature based on three of the DElncRNAs that served as an independent biomarker for predicting LGG patient outcomes after radiotherapy. In vitro experiments further validated the biological function of these lncRNAs on low-grade glioma radiation response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.